These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing. Wen J; Tao W; Hao S; Zu Y J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635 [TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 gene editing for curing sickle cell disease. Park SH; Bao G Transfus Apher Sci; 2021 Feb; 60(1):103060. PubMed ID: 33455878 [TBL] [Abstract][Full Text] [Related]
6. CRISPR in personalized medicine: Industry perspectives in gene editing. Hong A Semin Perinatol; 2018 Dec; 42(8):501-507. PubMed ID: 30376985 [TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges. Demirci S; Leonard A; Haro-Mora JJ; Uchida N; Tisdale JF Adv Exp Med Biol; 2019; 1144():37-52. PubMed ID: 30715679 [TBL] [Abstract][Full Text] [Related]
8. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. DeWitt MA; Magis W; Bray NL; Wang T; Berman JR; Urbinati F; Heo SJ; Mitros T; Muñoz DP; Boffelli D; Kohn DB; Walters MC; Carroll D; Martin DI; Corn JE Sci Transl Med; 2016 Oct; 8(360):360ra134. PubMed ID: 27733558 [TBL] [Abstract][Full Text] [Related]
9. Treatment of heritable diseases using CRISPR: Hopes, fears, and reality. Kofler N; Kraschel KL Semin Perinatol; 2018 Dec; 42(8):515-521. PubMed ID: 30420296 [TBL] [Abstract][Full Text] [Related]
10. Targeted Gene Manipulation in Plants Using the CRISPR/Cas Technology. Zhang D; Li Z; Li JF J Genet Genomics; 2016 May; 43(5):251-62. PubMed ID: 27165865 [TBL] [Abstract][Full Text] [Related]
11. [Genome editing in plants directed by CRISPR/Cas ribonucleoprotein complexes]. Li X; Shi W; Geng LZ; Xu JP Yi Chuan; 2020 Jun; 42(6):556-564. PubMed ID: 32694114 [TBL] [Abstract][Full Text] [Related]
12. A justice-based argument for including sickle cell disease in CRISPR/Cas9 clinical research. Baffoe-Bonnie MS Bioethics; 2019 Jul; 33(6):661-668. PubMed ID: 31107563 [TBL] [Abstract][Full Text] [Related]
13. The Cas9 Hammer-and Sickle: A Challenge for Genome Editors. Urnov FD CRISPR J; 2021 Feb; 4(1):6-13. PubMed ID: 33616446 [TBL] [Abstract][Full Text] [Related]
14. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing. Xu Y; Liu R; Dai Z Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813 [TBL] [Abstract][Full Text] [Related]
15. Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective. Zhang D; Hussain A; Manghwar H; Xie K; Xie S; Zhao S; Larkin RM; Qing P; Jin S; Ding F Plant Biotechnol J; 2020 Aug; 18(8):1651-1669. PubMed ID: 32271968 [TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine. Jacinto FV; Link W; Ferreira BI J Cell Mol Med; 2020 Apr; 24(7):3766-3778. PubMed ID: 32096600 [TBL] [Abstract][Full Text] [Related]
18. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease. Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808 [TBL] [Abstract][Full Text] [Related]
19. Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for Wei T; Cheng Q; Farbiak L; Anderson DG; Langer R; Siegwart DJ ACS Nano; 2020 Aug; 14(8):9243-9262. PubMed ID: 32697075 [TBL] [Abstract][Full Text] [Related]
20. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]